When a clinical-stage biotech is sitting on nearly $600 million in cash and lining up an FDA filing, sharp investors stop arguing about the past rally and start debating what comes next.On November 14, New York City-based Suvretta Capital Management disclosed a buy of 387,641 shares of Mineralys Therapeutics (MLYS 1.97%) that contributed to an overall position increase of about $57.25 million.What HappenedSuvretta Capital Management, a U.S.-based investment adviser, reported in a November 14 SEC filing that ...